Physician profile
Beth A Bilski
NPI 1750328076
$2,947.41
in general payments reported to CMS, 2019-2025
21 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $316 · 2021: $347 · 2022: $319 · 2023: $372 · 2024: $523 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,025.60 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $426.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.82 | 2019-2024 | Jardiance |
| Abbott Laboratories | $209.33 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $129.45 | 2019-2021 | |
| Lilly USA, LLC | $128.95 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $107.29 | 2022 | |
| Idorsia Pharmaceuticals US INC | $91.82 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $86.13 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.11 | 2024-2025 | Caplyta |
| Allergan, INC. | $61.75 | 2020 | |
| Glaxosmithkline, LLC. | $58.96 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $47.16 | 2021-2025 | Evenity |
| Abbvie INC. | $38.92 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $30.20 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $24.31 | 2020 | |
| Exact Sciences Corporation | $19.82 | 2025 | The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $16.87 | 2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $15.56 | 2024 | Veozah |
| Shire North American Group INC | $12.73 | 2019 | |
| Merck Sharp & Dohme LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Bilski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.